The Lancet11d
Rating the response of primary aldosteronism to targeted medical treatment with the PAMO criteria
The consequences of primary aldosteronism mainly result from the activation of the mineralocorticoid receptor. Two of these ...
Too Old to Operate4d
Optimizing Spironolactone Use With Sodium Zirconium Cyclosilicate in HFrEF
The following is a summary of “Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone ...
TCTMD12d
Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit
The message is that an early decrease in eGFR with finerenone should not lead to stopping the medication, say HF experts.
Healio11d
FDA clears investigational new drug application for lorundrostat in OSA, hypertension
The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...
Healio13d
Obesity medications can tackle metabolic cardiorenal disease
The effects of SGLT2 inhibitors on the kidney to prevent progression of chronic kidney disease, congestive heart failure, ...
The Lancet12d
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention
Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...
Medscape1d
Third-Generation Oral Contraceptives: Future Implications of Current Use
AR = Androgen receptor; ER = Estrogen receptor; GR = Glucocorticoid receptor; MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins ...
Renal & Urology News9d
Finerenone Increases Hyperkalemia Risk in Patients With Mild Heart Failure
In the trial of 6001 patients with heart failure and an ejection fraction of 40% or higher, treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), significantly ...